Compare GSBC & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | TXMD |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 21.3M |
| IPO Year | N/A | N/A |
| Metric | GSBC | TXMD |
|---|---|---|
| Price | $65.80 | $1.70 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $59.50 | N/A |
| AVG Volume (30 Days) | 50.2K | ★ 126.7K |
| Earning Date | 01-20-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 18.31 | N/A |
| EPS | ★ 6.00 | 0.03 |
| Revenue | ★ $228,683,000.00 | $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $10.89 | $277.12 |
| Revenue Growth | 7.86 | ★ 75.19 |
| 52 Week Low | $47.58 | $0.70 |
| 52 Week High | $66.98 | $2.44 |
| Indicator | GSBC | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 76.41 | 50.33 |
| Support Level | $61.24 | $1.46 |
| Resistance Level | $62.76 | $2.01 |
| Average True Range (ATR) | 1.10 | 0.17 |
| MACD | 0.52 | -0.02 |
| Stochastic Oscillator | 89.75 | 32.76 |
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.